(Total Views: 513)
Posted On: 09/13/2025 6:04:31 PM
Post# of 156897
Sept. 2024 Letter / Dr. J video / Mr. Hoffman:
Sept:
We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies ---- *with both antibody-drug conjugates ---- *and immune checkpoint inhibitors.
The Company intends to use this preclinical study to form the basis *-- for a potential partnership --* and better inform the design of a follow-up clinical study in patients with metastatic TNBC.
___
ADC & ICI: mTNBC trial wider than "just" ICI. ( outstanding )
Dr. J video now brings our PD-L1/ICI to 9 cancers.
Mr. Hoffman just said Cytodyn will be working with ICI's to help patients worldwide.
Days ago i said neither sound concerned over funding. Now, FDA officially closes our Brief submission.
A small funding for internal operations & we can finally, finally just sit back & watch Leronlimab command the stage.
Sept:
We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies ---- *with both antibody-drug conjugates ---- *and immune checkpoint inhibitors.
The Company intends to use this preclinical study to form the basis *-- for a potential partnership --* and better inform the design of a follow-up clinical study in patients with metastatic TNBC.
___
ADC & ICI: mTNBC trial wider than "just" ICI. ( outstanding )
Dr. J video now brings our PD-L1/ICI to 9 cancers.
Mr. Hoffman just said Cytodyn will be working with ICI's to help patients worldwide.
Days ago i said neither sound concerned over funding. Now, FDA officially closes our Brief submission.
A small funding for internal operations & we can finally, finally just sit back & watch Leronlimab command the stage.
(7)
(0)
